Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 5/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2040677 | 0.86 | NPSR1 (0.67) | NPSR1HSD17B10MPOHDAC1MEN1 | |
| SCHEMBL17699257 | 0.83 | PTGDR (0.42) | NPSR1HSD17B10MPOMTNR1AMTNR1B | |
| SCHEMBL17699259 | 0.76 | MTNR1A (0.42) | NPSR1MPOMTNR1AMTNR1BPTGDR | |
| SCHEMBL11001236 | 0.76 | GRM5 (0.48) | HDAC1ALDH1A1 | |
| SCHEMBL13506675 | 0.75 | HTR2A (0.45) | MPOPTGDRMEN1KMT2AHTR2A | |
| SCHEMBL21894334 | 0.74 | CYP1A2 (0.47) | HSD17B10HDAC1ALDH1A1 | |
| SCHEMBL2040233 | 0.73 | NPSR1 (0.50) | NPSR1HSD17B10HDAC1MEN1KMT2A | |
| SCHEMBL2042859 | 0.72 | NPSR1 (0.63) | NPSR1HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL2046992 | 0.72 | NPSR1 (0.50) | NPSR1HSD17B10HDAC1MEN1KMT2A | |
| SCHEMBL8348068 | 0.72 | GRM5 (0.50) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115132-A1 | NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-04-28 | — | — | US | claimed |
| US-20170037015-A1 | NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037015-A1 | NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF | TYR, MITF, TEAD3 | NPSR1 1708/4885HSD17B10 145/4885MPO 204/4885 |
| US-20160115132-A1 | NOVEL PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF | TYR, MITF, TEAD3 | NPSR1 1708/4885HSD17B10 145/4885MPO 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.